Placebo Tiotropium

DRUG2 trials

Sponsors

AstraZeneca, Boehringer Ingelheim

Conditions

Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic Obstructive

Phase 3

Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT00435760

AstraZenecaChronic Obstructive Pulmonary Disease (COPD)

Start: 2007-02-28End: 2007-08-31Updated: 2016-11-17

Phase 4

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

CompletedNCT00563381

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2008-01-31Updated: 2013-12-24

Related Papers

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD®

Advances in Therapy2015-06-0110 citations

Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.

2013-12-0536 citations

Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial

Respiratory Research2013-10-2982 citations

Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients.

2012-10-2614 citations

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

2011-03-01442 citations